» Articles » PMID: 35529883

β2-Integrins - Regulatory and Executive Bridges in the Signaling Network Controlling Leukocyte Trafficking and Migration

Overview
Journal Front Immunol
Date 2022 May 9
PMID 35529883
Authors
Affiliations
Soon will be listed here.
Abstract

Leukocyte trafficking is an essential process of immunity, occurring as leukocytes travel within the bloodstream and as leukocyte migration within tissues. While it is now established that leukocytes can utilize the mesenchymal migration mode or amoeboid migration mode, differences in the migratory behavior of leukocyte subclasses and how these are realized on a molecular level in each subclass is not fully understood. To outline these differences, first migration modes and their dependence on parameters of the extracellular environments will be explained, as well as the intracellular molecular machinery that powers migration in general. Extracellular parameters are detected by adhesion receptors such as integrins. β2-integrins are surface receptors exclusively expressed on leukocytes and are essential for leukocytes exiting the bloodstream, as well as in mesenchymal migration modes, however, integrins are dispensable for the amoeboid migration mode. Additionally, the balance of different RhoGTPases - which are downstream of surface receptor signaling, including integrins - mediate formation of membrane structures as well as actin dynamics. Individual leukocyte subpopulations have been shown to express distinct RhoGTPase profiles along with their differences in migration behavior, which will be outlined. Emerging aspects of leukocyte migration include signal transduction from integrins actin to the nucleus that regulates DNA status, gene expression profiles and ultimately leukocyte migratory phenotypes, as well as altered leukocyte migration in tumors, which will be touched upon.

Citing Articles

Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms.

Magnusen A, Pandey M Int J Mol Sci. 2024; 25(22).

PMID: 39596318 PMC: 11594573. DOI: 10.3390/ijms252212252.


Clinical significance of upregulated Rho GTPase activating protein 12 causing resistance to tyrosine kinase inhibitors in hepatocellular carcinoma.

Wang X, Tang Y, Li F, Wang J, Yao G, Zeng D World J Gastrointest Oncol. 2024; 16(10):4244-4263.

PMID: 39473957 PMC: 11514672. DOI: 10.4251/wjgo.v16.i10.4244.


Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.

Haage T, Charakopoulos E, Bhuria V, Baldauf C, Korthals M, Handschuh J J Hematol Oncol. 2024; 17(1):43.

PMID: 38853260 PMC: 11163796. DOI: 10.1186/s13045-024-01562-5.


Integrins in Health and Disease-Suitable Targets for Treatment?.

Klaus T, Hieber C, Bros M, Grabbe S Cells. 2024; 13(3.

PMID: 38334604 PMC: 10854705. DOI: 10.3390/cells13030212.


Selenomethionine Suppress the Progression of Poorly Differentiated Thyroid Cancer LncRNA NONMMUT014201/miR-6963-5p/Srprb Pathway.

Pan R, Zhao J, Yao J, Gao Y, Liao L Comb Chem High Throughput Screen. 2024; 27(16):2419-2432.

PMID: 38173060 DOI: 10.2174/0113862073286006231228070738.


References
1.
Kato Y, Miyakawa T, Tanokura M . Overview of the mechanism of cytoskeletal motors based on structure. Biophys Rev. 2017; 10(2):571-581. PMC: 5899727. DOI: 10.1007/s12551-017-0368-1. View

2.
Kameritsch P, Renkawitz J . Principles of Leukocyte Migration Strategies. Trends Cell Biol. 2020; 30(10):818-832. DOI: 10.1016/j.tcb.2020.06.007. View

3.
Krause M, Gautreau A . Steering cell migration: lamellipodium dynamics and the regulation of directional persistence. Nat Rev Mol Cell Biol. 2014; 15(9):577-90. DOI: 10.1038/nrm3861. View

4.
Smith A, Carrasco Y, Stanley P, Kieffer N, Batista F, Hogg N . A talin-dependent LFA-1 focal zone is formed by rapidly migrating T lymphocytes. J Cell Biol. 2005; 170(1):141-51. PMC: 2171377. DOI: 10.1083/jcb.200412032. View

5.
Rosenkranz A, Coxon A, Maurer M, Gurish M, Austen K, Friend D . Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol. 1998; 161(12):6463-7. View